CAJ | 학술논문

目的：观察米氮平联合艾司西酞普兰治疗卒中后抑郁的临床效果。方法将符合卒中后抑郁症诊断的脑卒中患者98例随机分为两组，治疗组50例在常规药物治疗及康复训练的基础上加用米氮平联合艾司西酞普兰抗抑郁治疗，对照组48例单采用神经科常规药物治疗及康复训练，两组患者分别在入选时及病程1、3、6个月进行日常生活能力(BI)和汉密尔顿抑郁量表(HAMD)评分。结果治疗前两组BI、HAMD评分差异无统计学意义(P>0.05)，治疗1、3、6个月后治疗组与对照组比较差异有统计学意义(P<0.05)。治疗组HAMD、BI评分于治疗3、6个月后显著改善(P<0.05)。结论米氮平联合艾司西酞普兰治疗卒中后抑郁具有显著临床疗效。患者抑郁症状改善的同时显著改善患者日常生活能力。
목적：관찰미담평연합애사서태보란치료졸중후억욱적림상효과。방법장부합졸중후억욱증진단적뇌졸중환자98례수궤분위량조，치료조50례재상규약물치료급강복훈련적기출상가용미담평연합애사서태보란항억욱치료，대조조48례단채용신경과상규약물치료급강복훈련，량조환자분별재입선시급병정1、3、6개월진행일상생활능력(BI)화한밀이돈억욱량표(HAMD)평분。결과치료전량조BI、HAMD평분차이무통계학의의(P>0.05)，치료1、3、6개월후치료조여대조조비교차이유통계학의의(P<0.05)。치료조HAMD、BI평분우치료3、6개월후현저개선(P<0.05)。결론미담평연합애사서태보란치료졸중후억욱구유현저림상료효。환자억욱증상개선적동시현저개선환자일상생활능력。
Objective To observe the clinical efficacy of mirtazapine combined escitalopram on treating post-stroke depression (PSD). Methods 98 patients with PDS diagnosed by Hamilton Depression Rating Scale (HAMD) were randomly divided into observation group and control group, control group (50 cases) with mirtazapine combined escitalopram therapy based on standardized treatment of stroke and rehabilitation. The control group (48 cases) only with standardized treatment of stroke and rehabilitation. Two groups were evulated and compared using Hamilton Depression Rating Scale (HAMD) and Barthel Index (BI) and compared before and after 1, 3, 6 months of treatment. Results There was no significant difference in HAMA and BI in two groups before treatment, the study group reduced rate of HAMA and increase rate of BI higher than that control group after 1, 3, 6 months. The improvement of HAMD, BI was significant in the control group after1, 3, 6 months of treatment. Conclusions Mirtazapine combined escitalopram has significant clinical effect in treatment of post-stroke depression, which can improve depressive symptoms and patients’daily life at the same time.